Peer

Epidemiological and genetic characteristics of swine pseudorabies virus in mainland China between 2012 and 2017

Ying Sun^{1,*}, Wan Liang^{1,2,*}, Qingyun Liu^{1,3}, Tingting Zhao^{1,3}, Hechao Zhu^{1,3}, Lin Hua^{1,3}, Zhong Peng^{1,3}, Xibiao Tang¹, Charles W. Stratton⁴, Danna Zhou², Yongxiang Tian², Huanchun Chen^{1,3} and Bin Wu^{1,3}

¹ The Cooperative Innovation Center for Sustainable Pig Production, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, China

² Key Laboratory of Prevention and Control Agents for Animal Bacteriosis (Ministry of Agriculture), Institute of Animal Husbandry and Veterinary Science, Hubei Academy of Agricultural Sciences, Wuhan, China

³ State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China

⁴ Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States of America

These authors contributed equally to this work.

ABSTRACT

The outbreak of pseudorabies (PR) in many Bartha-K61 vaccinated farms in China in late 2011 has seriously damaged the pig industry of one of the largest producers of pork products in the world. To understand the epidemiological characteristics of the pseudorabies virus (PRV) strains currently prevalent in China, a total of 16,256 samples collected from pig farms suspected of PRV infection in 27 Provinces of China between 2012 and 2017 were evaluated for detection of PRV. Since the extensive use of gEdeleted PRV vaccine in China, the PRV-gE was applied for determining wild-type virus infection by PCR. Of the 16,256 samples detected, approximately 1,345 samples were positive for the detection of PRV-gE, yielding an average positive rate of 8.27%. The positive rates of PRV detection from 2012 to 2017 were 11.92% (153/1284), 12.19% (225/1846), 6.70% (169/2523), 11.10% (269/2424), 5.57% (147/2640), and 6.90% (382/5539), respectively. To understand the genetic characteristics of the PRV strains currently circulating, 25 PRV strains isolated from those PRV-gE positive samples were selected for further investigation. Phylogenetic analysis based on gB, gC, and gE showed that PRV strains prevalent in China had a remarkably distinct evolutionary relationship with PRVs from other countries, which might explain the observation that Bartha-K61 vaccine was unable to provide full protection against emergent strains. Sequence alignments identified many amino acid changes within the gB, gC, and gE proteins of the PRVs circulating in China after the outbreak compared to those from other countries or those prevalent in China before the outbreak; those changes also might affect the protective efficacy of previously used vaccines in China, as well as being associated in part with the increased virulence of the current PRV epidemic strains in China.

Subjects Microbiology, Veterinary Medicine, Virology

Keywords Pseudorabies virus, Virus isolation, Phylogenetic analysis, Sequence alignment, PCR detection

Submitted 19 July 2018 Accepted 18 September 2018 Published 23 October 2018

Corresponding authors Zhong Peng, pengzhong@mail.hzau.edu.cn, pengzhong525@163.com Bin Wu, wub@mail.hzau.edu.cn

Academic editor Peirong Jiao

Additional Information and Declarations can be found on page 14

DOI 10.7717/peerj.5785

Copyright 2018 Sun et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

INTRODUCTION

Pseudorabies virus (PRV) mainly causes reproductive failure in sows as well as respiratory and neurological symptoms in piglets (*Mettenleiter*, 2000; *Nauwynck et al.*, 2007). PRV possesses a double-stranded liner DNA genome which contains more than 70 functional genes encoding proteins participating in the formation of viral capsid, tegument, and envelope (*Pomeranz, Reynolds & Hengartner*, 2005). Among these proteins, the envelope component proteins gB and gC induce cellular and humoral imMune responses (*Ober et al.*, 1998; *Ober et al.*, 2000), while gE acts as a major virulence determinant of PRV to pigs (*Kimman et al.*, 1992; *Wang et al.*, 2014). These three genes are commonly used for monitoring the evolution of PRV (*Muller et al.*, 2011; *Sozzi et al.*, 2014; *Yu et al.*, 2014; *Wang et al.*, 2015).

The first report of a PRV outbreak in China occurred in the 1950s. In the 1970s, an inactivated vaccine derived from PRV strain Bartha-K61 was imported from Hungary to China (Yuan et al., 1983; An et al., 2013). The widespread use of this vaccine in China was able to control outbreaks of pseudorabies between 1990 and 2011 (Tong & Chen, 1999). However, since late 2011, a pseudorabies (PR)-like disease has occurred in many Chinese pig farms that had been vaccinating pigs with the Bartha-K61 vaccine. PRV has been finally confirmed to be responsible for those outbreaks (An et al., 2013; Peng et al., 2013; Luo et al., 2014; Wang et al., 2014; Yu et al., 2014). A number of studies have noted that the Bartha-K61 vaccine appears to be unable to provide full protection against PRV strains isolated from those outbreaks (An et al., 2013; Wang et al., 2014; Yu et al., 2014). These findings suggest that there may be important changes in the PRVs currently circulating in China. However, genetic information as well as epidemiological data about PRV strains currently circulating in China is limited. Therefore, in this study, we report the detection/genetic analysis of PRVs recovered from pigs in China between 2012 and 2017. The aim of this study is to understand the epidemiological and genetic characteristics of PRVs that are currently prevalent in China.

MATERIALS AND METHODS

Samples collection and virus isolation

A total of 16,256 samples including tissue from lungs, lymph nodes, brains, serums, stillbirths, kidneys, and spleens were collected from pigs of different ages with signs suspected of PRV infection in farms (no. of sows \geq 100) in 27 Provinces in mainland China, excluding Ningxia and Tibet, between January, 2012 and December, 2016 (Fig. 1). The number of samples collected in 2012, 2013, 2014, 2015, 2016 and 2017 was 1,284, 1,846, 2,523, 2,424, 2,640 and 5,539, respectively. After collection, tissues were minced, immersed with Dulbecco's modified Eagle medium (DMEM), and homogenized using a QIAGEN TissueLyser II (QIAGEN Germany). Sample homogenates were then frozen at -80 °C and thawed for three times. Following centrifugation at 5,000 rpm for 5 min, the supernatants were harvested for DNA and/or virus isolation.

Template DNA for PCR detecting PRV was isolated using a Universe Genomic DNA Kit (CWBIO, Beijing, China) following the manufacturer's instructions. For virus isolation,



Figure 1 Samples collection from mainland China for PRV detection between 2012 and 2017. Full-size DOI: 10.7717/peerj.5785/fig-1

homogenate supernatants were filtered using a 0.22 μ m membrane, and inoculated into PK-15 cells (Purchased from ATCC, Manassas, VA, USA). Cells were then incubated in a 37 °C incubator supplemented with 5% CO2. Cell culture with obvious CPE was used for further plaque purification assays. Briefly, PK-15 cells were plated into a 6-well plate, and a series of 10-fold dilutions (from 10^{-1} to 10^{-6}) of virus was inoculated. The plate was incubated at 37 °C under an atmosphere containing 5% CO₂ for 2 h and was shaken one time every 15 min. After incubation, the virus was discarded and the cells were washed using DMEM for two times. Finally, DMEM medium containing 1% low melting agarose was added into each of the wells, and the plate was incubated at 4 °C until the medium solidified. The plate was then moved into a 37 °C cell incubator for plaque formation. Plaques with suitable size were selected and inoculated into 500 μ L DMEM, frozen and thawed for three times, and then diluted 2-fold in DMEM for the second round of plaque purification assay. After that, plaque fluid was inoculated into PK-15 cells and cultured in flask.

PRV detection

Polymerase chain reaction (PCR) assays were designed to detect the presence of PRV gE gene from the clinical samples using the DNA isolated as template as well as the primers listed in Table 1. The gE gene was used as the target gene because the gE-deleted pseudorabies virus (PRV) vaccine has been used in China extensively, and the detection of the gene could be applied for determining wild-type virus infection. As shown in Table 1, primers gE1-F and gE1-R were designed for the detection of gE. PCR reactions were performed in a 25 μ L

Table 1 P	rimers used in this study.		
Primers	Sequences (5'-3')	Products (bp)	Effects
gE1-F	CGTGTGGCTCTGCGTGCTGT	342	Sample detection
gE1-R	ATTCGTCACTTCCGGTTTC	542	Sample detection
gB2-F	GGCTGGTGGCGGTGTTTGGCG	892	Amplifying gB
gB2-R	AGGGCGAAGGAGTCGTAGGG	072	Ampinying gb
gC1-F	CCATGTGYGCCACTAGCATT	965	Amplifying the N-terminal of gC
gC1-R	CGGTGCTGTTGGTCACGAAG	205	Ampinying the N-terminal of ge
gC2-F	CAACGTCTCGCTCCTCCTGT	921	Amplifying the C-terminal of gC
gC2-R	GCCGTCGTCTCGTGTGGTT	921	Ampinying the C-terminal of gC
gE2-F	GACCATGCGGCCCTTTCTGC	899	Amplifying the N-terminal of gE
gE2-R	GGTCCACCGGGCGCAGGCA	077	Ampinying the N-terminal of gL
gE3-F	TTTACCGCCACGCTGGACTGGT	1,098	Amplifying the C-terminal of gE
gE3-R	CTTGGGGGGCCAGCAGGACGT	1,070	Ampinying the O-terminal of ge

volume mixture containing 12.5 μ L 2×Taq Master mix (TAKARA, Shiga, Japan), 8.5 μ L nucleotide-free water, each of the forward and reverse primers 1 μ L, 1 μ L DMSO, and 1 μ L template DNA. Thermocycler conditions used for PCR were 95 °C for 5 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C, 30 s for gE, and extension at 72 °C for 1 min, with a final extension at 72 °C for 10 min before storage at 4 °C. The PCR product was visualized using 1% agarose gel electrophoresis under ultraviolet light.

Sequencing and phylogenetic analysis

PCR assays were also designed for analysing the gB, gC, and gE genes of the PRVs currently circulating in China. The PCR volumes were the same as that used for PRV detection from the samples. Cycling conditions were 95 °C for 5 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 1 min, with a final extension at 72 °C for 10 min before storage at 4 °C. The PCR product was visualized using 1% agarose gel electrophoresis under ultraviolet light.

After amplification, PCR products were purified using a TIANgel Midi Purification Kit (Tiangen Biotechnique Inc., Beijing, China) and cloned into a pMD19-T vector (TAKARA, Shiga, Japan). Plasmids carrying either gB, gC, or gE were extracted and sent to Genscript (Nanjing, China) for DNA sequencing. The nucleotide sequences of gB, gC, and/or gE were edited and aligned (using BioEdit software) and then translated into aminoacids from each gene and then compared using DNAStar. Phylogenetic trees were generated through MEGA X, using neighbor-joining algorithm with 1,000 bootstrapping. Sequences of PRV strains listed in Table 2 retrieved from NCBI were used as references.

RESULTS

PCR detection of PRV in mainland China

Of the 16,256 samples, 1,345 samples were positive for the detection of PRV-gE, yielding an average positive rate of 8.27%. The positive rates of PRV detection from 2012 to 2017 were 11.92% (153/1284), 12.19% (225/1846), 6.70% (169/2523), 11.10% (269/2424),

Table 2PRV re	eference strains used in this stud	ly.	
Strain	Year of isolation	Place of isolation	GenBank accession
Bartha	—	Hungary	JF797217.1 (complete genome)
Becker	—	United States	JF797219.1 (complete genome)
Kaplan	—	Hungary	JF797218.1 (complete genome)
NIA3	—	Japan	KU900059.1 (complete genome)
Fa	2001	China	KM189913.1 (complete genome)
TJ	2012	China/Tianjin	KJ789182.1 (complete genome)
BJ/YT	2012	China/Beijing	KC981239.1 (complete genome)
ZJ01	2012	China/Zhejiang	KM061380.1 (complete genome)
HN1201	2012	China/Henan	KP722022.1 (complete genome)
HNX	2012	China/Henan	KM189912.1 (complete genome)
HeN1	2012	China/Henan	KP098534.1 (complete genome)
HLJ8	2013	China/Heilongjiang	KT824771.1 (complete genome)
Ea	1999	China/Hubei	AF257079.1 (gB), AF158090.1 (gC), AF171937.1 (gE)
GX-NL	2007	China/Guangxi	KT948044.1 (gB), KU323908.1 (gC), KT936469.1 (gE)
GD-SH	2007	China/Guangdong	KT948054.1 (gB), KU323907.1 (gC), EF552427.1 (gE)
GD-GZ	2009	China/Guangdong	KT948042.1 (gB), KU323905.1 (gC), KT936466.1 (gE)
GD-GZ2	2013	China/Guangdong	KT948045.1 (gB), KU323903.1 (gC), KT936467.1 (gE)
HN-CZ	2013	China/Hunan	KT948049.1 (gB), KU323912.1 (gC), KT936465.1 (gE)
GD-FS	2014	China/Guangdong	KT948040.1 (gB), KU323909.1 (gC), KT936476.1 (gE)
GD-HS2	2014	China/Guangdong	KT948047.1 (gB), KU323911.1 (gC), KJ660063.1 (gE)
GD-JM	2015	China/Guangdong	KT948048.1 (gB), KU323899.1 (gC), KT936473.1 (gE)
GD-QY	2010	China/Guangdong	KT948053.1 (gB), KU323901.1 (gC)
GX-GL	2013	China/Guangdong	KT948046.1 (gB), KU323910.1 (gC)
GD-YF	2015	China/Guangdong	KT948041.1 (gB), KU323904.1 (gC)
P-PrV	2003	Malaysia	EU915280.1 (gC), FJ176390.1 (gE)
LXB6	2009	China/Heilongjiang	GQ926931.1 (gC), GQ926932.1 (gE)
SMX	2014	China/Henan	KR025920.1 (gC), KP192495.1 (gE)
GD-WH	2015	China/Guangdong	KU323902.1 (gC), KT936468.1 (gE)
HNXX	2012	China/Henan	KJ526436.1 (gB), KJ526441.1 (gC)
HS	2008	China/Sichuan	EU719636.1 (gC)
Min-A	2002	China/Fujian	AY170318.1 (gE)

5.57% (147/2640), and 6.90% (382/5539), respectively. Monthly, higher positivity rates of PRV were detected in January, February, March, April, June, October, November and December; and winter (December, January and February), spring (March, April, and May) and autumn (September, October and November) were the seasons with the high positivity rate of PRV detection during 2012 and 2017 (Figs. 2A and 2B).

Mainland China is divided into seven parts including Northeastern China, Northern China, Eastern China, Central China, Southern China, Northwestern China, and Southwestern China (Fig. 1). Among these graphic regions, the positive rates of PRV detection in Eastern China and Central China between 2012 and 2017 were higher than 10.00%, while the positive rates in other parts of China between 2012 and 2017 ranged





Figure 2 Positivity rate of PRV detection in different months (A) and seasons (B). Full-size DOI: 10.7717/peerj.5785/fig-2

from approximately 7.00% and 10.00% (Fig. 1). In addition, the positivity rate of PRV detection in different graphic regions between different years displayed diversity. For instance, the positive rates of PRV detection in Northern China in 2012, 2013 and 2015 were higher than 15.00%, but the positivity rates in 2014 and 2016 were lower than 5.00%; the positive rate of PRV detection in Southwestern China in 2012 was 26.15%, while it was only 1.80% in 2013, and 6.90% in 2014, 5.97% in 2015, but zero in 2016; in Northwestern China, the positivity rate of PRV detection in 2012 and 2013 were higher than 20.00%, and approximately 10.40% in 2014 and 2015, but zero in 2016 (Fig. 3).



PRV isolation

To understand the genetic characteristics of PRVs currently circulating in China, a total of 25 PRV strains isolated herein were used for further analysis in this study (Table 3). Most of those strains were isolated from lungs and their $TCID_{50}/0.1$ mL values ranged from $10^{6.72}$ to $10^{7.96}$.

Phylogenetic characteristics

Phylogenetic analysis using gB, gC, and/or gE sequence showed that the PRV isolates from China were located on a phylogenetic branch, which was distinct from the those isolates from other countries of the world (Figs. 4A, 4B, 4C). According to previous study (*Ye et al., 2015*), those isolates from China belonged to genotype II, while those isolates from the other parts of the world including Bartha, Becker, Kaplan, and NIA3 were genotype I strains. Interestingly, one isolate from China in 2016, which we designed HuB, should be determined as a genotype II strain (Fig. 4B) according to Ye's study, in which PRVs were phylogenetically divided into two major genotypes, genotype I and genotype II, based on the analysis of gC gene (*Ye et al., 2015*). However, this isolate had a closer relationship to the genotype I strains when using gB to perform the phylogenetic analysis (Fig. 4A).

Analysis of gB, gC and gE


The maximal amino acid sequence divergence for gB, gC, and gE proteins of the 25 PRV isolates were 5.2, 2.7, and 2.6% within the isolates, and were 8.4, 9.2, and 5.5% compared to those isolates from the other countries, respectively. The maximal amino acid sequence divergence for the three proteins of the 25 isolates were 4.8, 9.9, and 2.8% compared to those strains prevalent in China before 2012, and were 4.8, 2.7, and 2.8% after 2012.


Alignment of amino acid sequences of gB found the isolates from China mainly had three types of mutations within the protein compared those strains from the other countries. The

Table 3 Twe	nty-five strains of PKV	isolated and analyzed in	tnis study.	
Strains	Place of isolation	Samples of isolation	Date of isolation	TCID50/0.1 mL
HeNFJC	Henan	Lung	2015/11	10 ^{6.72}
HeNJYG	Henan	Lung	2015/11	10 ^{7.38}
GDFC	Guangdong	Lung	2016/3	$10^{7.00}$
GD	Guangdong	Lung	2016/3	10 ^{7.25}
HeNZZZM	Henan	Lung	2016/3	10 ^{7.25}
HuBLLP	Hubei	Lung	2016/3	10 ^{7.59}
FJFQ	Fujian	Lung	2016/3	10 ^{7.28}
GDHDYC	Guangdong	Lung	2016/3	10 ^{7.49}
HuN	Henan	Brain	2016/3	10 ^{7.96}
SDRZ	Shandong	Lymph nodes	2016/3	10 ^{7.36}
HuBYCYJ	Hubei	Lymph nodes	2016/4	10 ^{7.67}
HeNXY	Henan	Lung	2016/4	$10^{7.08}$
HuBWX	Hubei	Lung	2016/4	10 ^{7.25}
SDSCL	Shandong	Lung	2016/5	$10^{7.80}$
HuBHC	Hubei	Lung	2016/5	10 ^{7.59}
HuBAL	Hubei	Brain	2016/9	10 ^{7.12}
HuBZX	Hubei	Brain	2016/9	$10^{7.40}$
ZJHY	Zhejiang	Lung	2016/10	10 ^{7.25}
SX	Shanxi	Lung	2016/10	10 ^{7.57}
HeNXP	Henan	Brain	2016/11	10 ^{7.25}
HuBHZ	Hubei	Lung	2016/11	10 ^{7.12}
HuBQJ	Hubei	Lung	2016/11	$10^{7.00}$
HuB	Hubei	Tonsil	2016/12	10 ^{7.35}
JSZL	Jiangsu	Brain	2016/12	10 ^{7.43}
HuBSP	Hubei	Brain	2016/12	$10^{7.54}$

isolates from China harbored an-amino acid insertion at site 94 (G), a substitution of ten amino acids at sites 53 (A \rightarrow T), 55 (P \rightarrow T), 70 (T \rightarrow A), 81 (N \rightarrow D), 82 (D \rightarrow G), 83 (V \rightarrow F), 87 (A \rightarrow E), 93 (E \rightarrow D), 96 (F \rightarrow V) and 102 (E \rightarrow D), and a deletion of three-amino acids at sites 75–77 (S, P and G) compared to Bartha-Hungary, Kaplan-Hungary and NIA-3-Japan. In addition, there were also some different substitutions at different sites within the gB protein of the 25 isolates compared to Bartha-Hungary. For example, HuBHZ-China-2016 harbored a substitution of one amino acid at sites 11 (P \rightarrow A) and 12 (R \rightarrow G), while strains JSZL-China-2016, HuB-China-2016, and SDRZ-China-2016 had an amino acid substitution at sites 12 (R \rightarrow H), 67 (A \rightarrow V), and 228 (K \rightarrow E), respectively (Fig. 5).

For the gC protein, the isolates from China had an insertion of seven amino acids at sites 63-69 (A, A, A, S, T, P and A) within the protein compared to the genotype I strains; while strain LXB6-China-2009 harbored an insertion of six amino acids at sites 64-69 (A, A, S, T, P and A). In particular, those isolates from China after 2012 contained a substitution of twenty-three amino acids substitutions at sites 14 (P \rightarrow L), 16 (A \rightarrow T), 52 (P \rightarrow S), 55 (A \rightarrow E), 57 (A \rightarrow V), 59 (P \rightarrow G), 60 (E \rightarrow T), 76 (A \rightarrow V), 87 (P \rightarrow Q), 90 (N \rightarrow G), 102 (A \rightarrow S), 130 (F \rightarrow V), 163 (S \rightarrow P), 186 (T \rightarrow A), 188 (V \rightarrow A), 190 (E \rightarrow V), 191 (D \rightarrow V), 243





Full-size DOI: 10.7717/peerj.5785/fig-4

 $(S \rightarrow H)$, 431 (L \rightarrow M), 449 (A \rightarrow T), 457 (S \rightarrow T), 461 (V \rightarrow T) and 467 (G \rightarrow A) compared to the genotype I strains (Fig. 6). In addition, some other substitutions were also found during the analysis: HuN-China-2016, SDRZ-China-2016, HuB-China-2016, HuN-China-2016, HuBAL-China-2016, and SDRZ-China-2016 harbored amino acid substitutions at sites 106 (K \rightarrow T), 107 (R \rightarrow C), 210/227 (A \rightarrow T), 235 (A \rightarrow V), 300 (L \rightarrow P) and 386 (W \rightarrow R), respectively.

The sequence alignments of the gE protein found also found some amino acid mutations within the protein of the genotype II strains compared to the genotype I isolates. Compared with Kaplan-Hungary and NIA3-Japan, the 25 isolates contained an insertion of one amino acid (D) at site 48 (Fig. 7). Compared with Min-A-China-2002, the 25 isolates contained a deletion of one amino acid (D) at site 493. In particular, HeNJYG-China-2016, HuBWX-China-2016, HeNXY-China-2016 and GDHDYC-China-2016 deleted an amino acid (D) at site 491, while HuN-China-2016 and SDRZ-China-2016 had a deletion of one amino acid at sites 489 (Y) and 495 (D) compared to Min-A-China-2002, respectively; strain HuB-China-2016 deleted four amino acids (DLNG) at sites 61-64 compared to Min-A-China-2002. In addition to amino acid deletion, sequence alignments also identified amino acid substitutions within the gE protein of the strains isolated herein. For example, strains HeNJYG-China-2016, HuBHZ-China-2016, HuBHZ-China-2016, HuBLLP-China-2016, HuN-China-2016, HuN-China-2016, HuBHZ-China-2016 contained one amino acid substitution at sites 336

Peer

		20	30	40	50		60	70	e de Mariae	30	90		100	110	120
barona nangary	RGPRGHRPG	HHGGAGLGRI	WPAPHHAAA	ARGAVALAI	ILLALA.	APPC	GAAAVTRAASASE	TPVP	SPGI	TPNDVSAE	LEE	E	FTPGPSEAR	DGEYGDLDART-	AV
Becker-USA	•••••					• • • •	•••••	GT				••		• • • • • • • • • • • • •	
Kaplan-Hungary							••••••					•		•••••	AVRA
NIA3-Japan						• • • •	••••••••••••••••••••••••••••••••••••••	GT			.G.	•••	.s	• • • • • • • • • • • • •	
Fa-China-2001						Τ.Τ.	• • • • • • • • • • • • • •	A.GT	7	DGF.T.I		DG	VSD	• • • • • • • • • • • • •	
Ea-China-1999						T.T.	• • • • • • • • • • • • • • •	A.GT		DGF.T.I		DG	VSD	• • • • • • • • • • • • •	
HeN1-China-2012						Τ.Τ.		A.GT		DGE1		DG	VSD	• • • • • • • • • • • • • •	
TJ-China-2012						T.T.		A.GT		DGF1		DG	VSD		
HuBHC-China-2016						T.T.		A.GT		DGF1		DG	VSD		
HuBYCYJ-China-2016						T.T.	• • • • • • • • • • • • • • • •	A.GT		DGF1		DG	VSD	• • • • • • • • • • • • •	
HuBWX-China-2016						Т.Т.		A.GT	1	DGE1		DG	VSD		
HuBZX-China-2016						т.т.		A.GT	1	DGFI		DG	VSD		
HuBAL-China-2016						Τ.Τ.		A.GT	1	DGE1		DG	VSD		
HuBHZ-China-2016	AG					T.T.		A.GT		DGF1		DG	VSD		
HuBLLP-China-2016						Т.Т.		A.GT		DGE		DG	VSD		
HuBQJ-China-2016						T.T		A.GT	1	DGF1		DG	VSD		
HuB-China-2016												DG	VSD		
HuBSP-China-2017						T.T.		A.GT		DGF1		DG	VSD		
FJFQ-China-2016						Т.Т.		A.GT		DGEI		DG	VSD		
HeNZZZM-China-2016						T.T.		A.GT		DGFI		DG	VSD		
HeNXY-China-2016						T.T.		A.GT		DGF		DG	VSD		
HeNXP-China-2016						T.T.		A.GT				DG	VSD		
HeNJYG-China-2015						Т.Т.		A.GT				DG	VSD		
HeNFJC-China-2015						T.T.		A.GT				DG	VSD		
GDHDYC-China-2016						T.T.		A.GT				DG	VSD		
GD-China-2016						T.T.		A.GT				DG	VSD		
GDFC-China-2016						T.T.		A.GT				DG	VSD		
3DRZ-China-2016						T.T		A.GT				DG	VSD.		
SDSCL-China-2016						T.T		A.GT		DGF		DG	VSD.		
HuN-China-2016						T.T.		A.GT		DGF		DG	VSD.		
JHY-China-2016						T.T		A.GT		DGE		DG	VS D		
SX-China-2016						T.T		A.GT		DGE		DG	VS. D		
JSZL-China-2017	н					T.T.		A GT		DGF 1		DG	VS. D		
/201-China-201/						A 1 A 1		dig 1				00			

Figure 5 Alignment of partial amino acid sequences of PRV gB protein. The substitution regions are shown by the green boxes. The deletion region is shown by the red box.

Full-size DOI: 10.7717/peerj.5785/fig-5


 $(D \rightarrow G)$, 2 $(R \rightarrow G)$, 473 $(T \rightarrow M)$, 49 $(L \rightarrow R)$, 573 $(A \rightarrow T)$, and 526 $(D \rightarrow G)$ compared to the genotype I strains, respectively. Particularly, one strain, SDRZ-China-2016, contained four substitutions at sites 407 $(V \rightarrow L)$, 487 $(E \rightarrow D)$, 499 $(E \rightarrow D)$ and 535 $(E \rightarrow D)$ compared to the genotype I strains.

DISCUSSION

PRV is a common threat to the pig industry worldwide and is particularly important in China. The outbreak of PR in China in late 2011 has seriously damaged the pig industry of one of the largest producers of pork products in the world (*An et al., 2013*; *Yu et al., 2014*). The present study reported the prevalence of PRV in China between 2012 and 2017. This report is the first large-scale etiological investigation of PRV involved in most regions of China following the outbreak. The data revealed an average positive rate of 8.27% for PRV detection during the six years, and higher than 6.9% positivity rate of PRV detection in different regions in China (Fig. 1). While there is a lack of similar data from the other studies, a nationwide surveillance detecting the PRV-gE antibody revealed that the positive rate of PRV-gE antibody in China during 2013–2016 was higher than 13.74% (*Liu et al., 2018*). These findings confirm that the prevalence of PRV remains a problem in China.

20 30 40 50 60 70 80 90 100 110 120 133 Bartha-Hungary Becker-USA Kaplan-Hungary L. LL FYAAFIAAPPTTRLGTPRGGGGSMSAGELSPSDPTFAPAAPELG FV. VSTERAF PSVSRRPPRNNN PRVHDERMAAFGRATUCEELISARVGDAVSGCAVFE MIA3-Japan L </th <th>-</th> <th>n i</th> <th></th>	-	n i																
Decker USA L D E FV FV Kaplan-Hungary L E FV C.G. S. JIXB-Gapan L C FV C.G. S. JIXB-Ghina-2009 L.T. S. F C.G. S. V. Garchina-1999 L.T. S. F.C. FV C.G. S. V. Bulke-China-2012 L.T. S. T.G. S. E.V.GT. AAASTER V. G.G. S. V. JU-China-2012 L.T. S. S. E.V.GT. AAASTER V. G.G. S. V. G.G. S. V. V. G.G. S.		i	1 ° -	20	30	40	5	0 60	1 C	70	1	80	90	· 1	DO	110	120	130
Becker-USA L D E	Bartha-Hungary	LL	PYAA	IAAAPST	TTALGTTPNG	GGGNSSAGE	LSPSP	PPTPAPASPE/	G	AVST	PRAP	PSVSRRK	PPRNNN	RTRVHGDK	ATAH	RKRIVCRERLI	SARVGDAVSFG	AVFE
NIA3-Japan L. T		.	L		D	E					.PV.							
NIA3-Japan L. T	Kaplan-Hungary	.	L			E										.E		
DADS CHIME 2001 L.T. S. E. V. GT. JAASTPP. PV C. G. S. S. S. V. Ear-China-1999 L.T. S. T. S. E. V. GT. JAASTPP. V. C. G. S. S. V. HeNI-China-2012 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. S. V. HUBCC-China-2012 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBWC-China-2016 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBWC-China-2016 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBWZ-China-2016 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBAL-China-2016 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBAL-China-2016 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBAL-China-2016 L.T. S. S. E. V. GT. JAASTPP. V. C. G. S. V. HUBQU-China-		.	L			E												
Ea-China-1999 L.T. S. T. S. E. V.GT. AAASTEZ V. Q. G. E. S. V. HeHI-China-2012 L.T. S. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HuBC-China-2012 L.T. S. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBC-China-2016 L.T. S. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBWX-China-2016 L.T. S. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBWX-China-2016 L.T. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBWX-China-2016 L.T. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBAL-China-2016 L.T. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBAL-China-2016 L.T. S. S. E. V.GT. AAASTEZ V. Q. G. S. V. HUBQU-China-2016 L.T. S. S. E. V.GT. AAASTEZ V. Q. G.	LXB6-China-2009	.							AASTP/				.QG.					⊽.
La CHIA 192012 L.T. S. S. E. V. GTL ABASTER . V TJ-Chia-2012 L.T. S. S. E. V. GTL ABASTER . V ULTCHia-2012 L.T. S. S. E. V. GTL ABASTER . V UBHC-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V HUBKC-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V HUBXC-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V HUBXC-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V HUBXC-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V G. G. . S. . V HUBXC-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V G. G. . S. . V HUBH2-Chia-2016 L.T. S. S. E. V. GTL ABASTER . V G. G. . S. . V HUBChia-2016 L.T. S. S. E. V. GTL ABASTER . V G. G. . S. . V HUBChia-2016 L.T. S. S. E. V. GTL ABASTER . V G. G. . S. . V HUBChia-2016<		.											.QG.	R				⊽.
Henk 2012 L.T. S. S. E. V. GT. ARASTER V. HUBHC-China-2012 L.T. S. S. E. V. GT. ARASTER V. HUBWC-China-2016 L.T. S. S. E. V. GT. ARASTER V. HUBWC-China-2016 L.T. S. S. E. V. GT. ARASTER V. HUBWC-China-2016 L.T. S. S. E. V. GT. ARASTER V. HUBWC-China-2016 L.T. S. S. E. V. GT. ARASTER V. HUBAC-China-2016 L.T. S. S. E. V. GT. ARASTER V. HUBAC-China-2016 L.T. S. S. E. V. GT. ARASTER V. HUBAC-China-2016 L.T. S. S. E. V. GT. ARASTER V. C. G. S. V. HUBQC-China-2016 L.T. S. S. E. V. GT. ARASTER V. C. G. S. V. HUBQC-China-2016 L.T. S. S. E. V. GT. ARASTER V. C. G. S. V. HUBQC-China-2016 L.T. S. S. E. V. GT. ARASTER V. C. G. S. V. HUBQC-China-2017 L.T. S. S. E. V.	Ea-China-1999	.		8	8T.								.QG.	E				⊽.
10 C111111 C1111111 C111111 C111111 C111111 C1111111 C1111111 C1111111 C1111111 C1111111111 C111111111111 C1111111111111 C111111111111111111111111111111111111	HeN1-China-2012	.		8	3								.QG.					⊽.
Hubry China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubry China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubry China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubry China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubla China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubla China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubla China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubla China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubla China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. Hubla China 2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. PUQChina 2016 </td <td>TJ-China-2012</td> <td> · ·</td> <td></td> <td> 8</td> <td>3</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>.QG.</td> <td></td> <td></td> <td></td> <td></td> <td>⊽.</td>	TJ-China-2012	· ·		8	3								.QG.					⊽.
Hubbrechina-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBW-China-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBAC-China-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBAC-China-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBAC-China-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBLP-China-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBUP-China-2016 L.T. S. S. E. V. GT. ARASTER . V. HubBUP-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HuBS-China-2017 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HuBS-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HuBS-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HeNXY-China-2016 L.T. S. E. V. GT. ARASTER . V. C. G. . S. . V.		· ·		8	3								.QG.					⊽.
Hubart Link 2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hubart-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hubart-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hubart-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hubart-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hub-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hub-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hub-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hub-China-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. Hub-Zzewchina-2016 L.T. S. S. P. V.GT. ARASTPR V. Q. G. S. V. HeNY2-China-2016		; . .		8	· · · · · · · · · · · · · · · · · · ·					• • • •			· × · · · · ·					⊽.
HubBAT-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HuBAT-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HuBLAT-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HuBLAT-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HuBQU-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HuBSP-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. FUPQ-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HUBSP-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HeMXY-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HeMXY-China-2016 L.T. S. S. E. V. GT. AAASTPP. V. Q. G. S. V. HeM				8	· · · · · · · · · · · · · · · · · · ·					• • • •								⊽.
HubBarchina 2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HubBarchina 2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HubBarchina 2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HubCy-China-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HuBS-China-2017 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HuBS-China-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. PURC-China-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeNX2-China-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeNX2-China-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeNX2-China-2015 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. <tr< td=""><td></td><td></td><td></td><td> 8</td><td>· · · · · · · · · · · · · · · ·</td><td></td><td></td><td></td><td></td><td>• • • •</td><td></td><td></td><td></td><td></td><td></td><td>•••••</td><td></td><td>⊽.</td></tr<>				8	· · · · · · · · · · · · · · · ·					• • • •						•••••		⊽.
HubLLP-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HubLLP-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HubSD-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HuBSD-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HuBSD-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. FURO-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HUBSD-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HeNZZ2M-China-2016 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HeNZC-China-2015 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S. . V. HeNYC-China-2015 L.T. S. S. E. V. GT. ARASTER . V. C. G. . S.				8	· · · · · · · · · · · · · · · · · · ·					• • • •						•••••		⊽.
HubQr-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HuBQr-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HuBSP-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HuBSP-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HeMX2-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HeMX2-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HeMXY-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HeMXY-China-2016 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. HeMYDC-China-2015 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V. GDHDYC-China-2015 L.T. S. S. E. V. GT. AAASTPA .V. Q. G. .S. .V.		ŀ.			· · · · · · · · · · · · · · · · · · ·					• • • •			· × · · · · ·					⊽.
HubPChina 2016 L.T. S. E. V.GTI. ARASTPR. PV C. G. S. L. V. HubPChina 2017 L.T. S. S. S. E. V.GTI. ARASTPR. V. C. G. S. S. V. HubPChina 2016 L.T. S. S. S. E. V.GTI. ARASTPR. V. C. G. S. S. V. PUPC China 2016 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. HeNZ32M-China 2016 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. HeNX7-China 2016 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. HeNX7-China 2016 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. GD/China 2015 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. GDUDYC-China 2015 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. GDPC-China 2016 L.T. S. S. E. V.GTI. ARASTPR. V. C. G. S. V. GDPC-China 2016		ŀ.			· · · · · · · · · · · · · · · · · · ·					• • • •			· × · · • ·					⊽.
Hubse-China-2017 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. FURDC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNZ22M-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNX22M-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNXPC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNYC-China-2015 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNYC-China-2015 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDHOYC-China-2015 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDPC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDPC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V.	HuBQJ-China-2016			8	· · · · · · · · · · · · · · ·					• • • •								⊽.
Haussen einer 2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNX2ZM-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNX2ZM-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNXP-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNXP-China-2015 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. HeNYPC-China-2015 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDHDYC-China-2015 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDHDYC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDPC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. GDPC-China-2016 L.T. S. S. E. V. GT. ARASTER .V. C. G. .S. .V. <td></td> <td></td> <td></td> <td>• • • • • • •</td> <td></td> <td>•••••</td> <td></td> <td></td> <td></td> <td>• • • •</td> <td></td> <td></td> <td>· × · · · · ·</td> <td></td> <td></td> <td>•••••</td> <td></td> <td>⊽.</td>				• • • • • • •		•••••				• • • •			· × · · · · ·			•••••		⊽.
Horverthina-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeMX22trina-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeMX27-China-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeMX7C-china-2015 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. HeMY0C-china-2015 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. GDUCC-china-2015 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. GDUCC-china-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. GDPC-china-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. SDB2-china-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V. SDB2-china-2016 L.T. S. S. E. V. GTL ARASTER .V. C. G. .S. .V.				8						• • • •			· · · · · · ·					⊽.
Heinbark Grind 2010 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. HeiNY2-China-2016 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. HeiNY2-China-2015 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. HeiNY2-China-2015 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. HeiNY2-China-2015 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. GDHOYC-China-2016 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. GDP-China-2016 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. GDP-China-2016 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. SDR2-China-2016 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. SDR2-China-2016 L.T. S. S. E. V. GTL ARASTER V. Ç. G. S. V. SDR2-China-20					· · · · · · · · · · · · · · · · · · ·					• • • •			. x			•••••		⊽.
HetNZ-China-2015 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. HetNZ-China-2015 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. GDHDYC-China-2015 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. GDHDYC-China-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. GDPCCChina-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. GDPC-China-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. GDPC-China-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. SDB2-China-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. SDB2-China-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. SDB2-China-2016 L.T. S. S. E. V. GT. AAASTPA V. Q. G. S. V. SDB2-China-2016 <td></td> <td></td> <td></td> <td> 8</td> <td></td> <td>••••••</td> <td></td> <td></td> <td></td> <td>• • • •</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>•••••</td> <td></td> <td>⊽.</td>				8		••••••				• • • •						•••••		⊽.
Henky China 2015 L.T. S. S. E.V.GTLARSTPAV. Ç.G. S. V. HeNYG-China-2015 L.T. S. S. E.V.GTLARSTPAV. Ç.G. S. V. GDEDVC-China-2016 L.T. S. S. E.V.GTLARSTPAV. Ç.G. S. V. GDPCC-China-2016 L.T. S. S. E.V.GTLARSTPAV. Ç.G. S. V. GDPC-China-2016 L.T. S. S. E.V.GTLARSTPAV. Ç.G. S. V. GDPC-China-2016 L.T. S. S. E.V.GTLARSTPAV. Ç.G. S. V. GDPC-China-2016 L.T. S. S. E.V.GTLARSTPAV. Q.G. S. V. SDB2C-China-2016 L.T. S. S. E.V.GTLARSTPAV. Q.G. S. V. SDB2C-China-201				8	3											•••••		∀.
Ineword China 2013 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. V. GDHUTC-China-2016 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. V. GD-China-2016 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. V. GD-China-2016 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. V. GDPC-China-2016 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. V. SDR2-China-2016 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. V. SDR2-China-2016 L.T. S. S. E. V. GTT. ARASTER V. C. G. S. C. V. SDR2C-China-2016 L.T. S. S. E. V. GT. ARASTER V. C. G. S. C. V. SDR2C-China-2016 L.T. S. S. E. V. GT. ARASTER V. C. G. S. T. V.		ŀ		8	3													⊽.
newrod Cunnar 2013 L.T. S. S. E. V. GTL ARASTER V. G. G. S. V. GDDDVC-Chinar-2016 L.T. S. S. E. V. GTL ARASTER V. G. G. S. V. GDPC-Chinar-2016 L.T. S. S. E. V. GTL ARASTER V. G. G. S. V. GDPC-Chinar-2016 L.T. S. S. E. V. GTL ARASTER V. G. G. S. V. SDR2-Chinar-2016 L.T. S. S. E. V. GTL ARASTER V. G. G. S. V. SDR2-Chinar-2016 L.T. S. S. S. V. G. G. S. V. SDR2-Chinar-2016 L.T. S. S. S. V. G. G. S. V. SDRC-Chinar-2016 L.T. S. S. S. V. G. G. S. V. SDRC-Chinar-2016 L.T. S. S. S. V. G. G. S. V.		ŀ.		8												•••••		⊽.
GD=China=2016 L.T. S. S. F. V. GTL AAASTPA V. C.G. S. V. GD=China=2016 L.T. S. S. S. V. GDEC-China=2016 V. V. Q.G. S. V. V. GDEC-China=2016 V. V. Q.G. S. V. SDEC-China=2016 V. V. Q.G. S. V. SDEC-China=2016 V. V. SDEC-China=2016 V. S. S. V. SDEC-China=2016 S. V. S. S. V. SDEC-China=2016 S. S. V. SDEC-China=2016 S. S. V. S. S. V. SDEC-China=2016 S. S. V. S. S. V. SDEC-China=2016 S. S. V. V. SDEC-China=2016 S.		ŀ.		8	· · · · · · · · · · · · · · · · · · ·											•••••		⊽.
GD China 2016 L.T. S. S. E.V.GT. AAASTER V. Ç.G. S. V. SDBCC-China-2016 L.T. S. S.E.V.GT. AAASTER V. Ç.G. S. V. SDBCC-China-2016 L.T. S. S.E.V.GT. AAASTER V. Ç.G. S. S. V. SDBCL-China-2016 L.T. S. S.E.V.GT. AAASTER V. Ç.G. S. V. HW-China-2016 L.T. S. S.E.V.GT. AAASTER V. Ç.G. S. V.		ŀ		8	3											•••••		⊽.
SDRZ-China-2016 I.T. S. S. V. Q.G. S. C. V. SDRZ-China-2016 I.T. S. S. V. Q.G. S. V. V. Q.G. S. V. V. Q.G. S. V. V. V. Q.G. S. V. V. V. Q.G. S. V.				8	3					• • • •			· X · · · · ·			•••••		∀.
SDSCI-china-2016 L.T. S. S. E.V. GTI AAASTPA V. Q.G. S. V. HuN-China-2016 L.T. S. S. E.V. GTI AAASTPA V. V. Q.G. S. V. V.		ŀ		8						• • • •			· X · · · · ·					⊽.
DBCCD CHIM 2016 . L.T		ŀ.		8	3					• • • •						c		⊽.
nuw chille 2010		ŀ.			· · · · · · · · · · · · · · · · · · ·					• • • •								⊽.
		ŀ		8	3					• • • •						.T		⊽.
2011 Chilla 2016	ZJHY-China-2016	· ·	L.T.	8	· · · · · · · · · · · · · · ·			.SE.V.GT	. AAASTPI				.QG.		s.	•••••		⊽.
SX-China-2016 L.T		· ·		8	· · · · · · · · · · · · · · · · · · ·					• • • •						•••••		⊽.
JS2L-China-2017 L.TS	JSZL-China-2017	ŀ	L.T.	8	3			.SE.V.GT	.AAASTPA	• • • •	∀.		.QG.		s.	•••••		⊽.

· · ·	140	150	60	170	180	190	200	210	220	230	240 4	0 440	450	460
	RFYRRGF	FRSPDADP	EYFDEPPR	ELPRERLLFS	BANASLAHA	DALTPVVEDEG	RATVANVSGEV	SVRVAAADAE	TEGVYTWRVL	SANGTEVRSANV	LLLYSO	LPSCLPVF ZDYCRY		
Becker-USA														
Kaplan-Hungary						Α.								
NIA3-Japan						AVV								
LXB6-China-2009						ASA.VV					.V.H.	1	7 7	F. F. A.
Fa-China-2001						ASA.VV	K.				.V.H.	1		I. I. A.
Ea-China-1999	c					ASA.VV					.VH.	II		II
HeN1-China-2012	c					ASA.VV					.V.H.	II		ll.
TJ-China-2012	c					ASA.VV					.VH.	I I.		I. I. A.
HuBHC-China-2016	c					ASA.VV					.VH.	I I		II
HuBYCYJ-China-2016						ASA.VV					.VH.	II		IIA.
HuBWX-China-2016	c					ASA.VV					.VH.	II		IIA.
HuBZX-China-2016	c		· · · · · · · · · · · · · · · · · · ·			ASA.VV					.VH.	II		ll
HuBAL-China-2016	c		· · · · I			ASA.VV					.VH.	II		II
HuBHZ-China-2016	c		· · · · I			ASA.VV					.VH.	II		IIA.
HuBLLP-China-2016	c		· · · · · · · · · · · · · · · · · · ·			ASA.VV					.VH.	II		II
HuBQJ-China-2016	c					ASA.VV					.VH.	II		IIA.
HuB-China-2016			· · · · I			A.A.VV		T		.T	.VH.	<u>.</u>		IIA.
HuBSP-China-2017	c		· · · · I			ASA.VV					.VH.	II		IIA.
FJFQ-China-2016	c		· · · • • • • • • • • • • • • • • • • •	.		ASA.VV					.VH.	II		IIA.
HeNZZZM-China-2016	;		· · · · · · · · · · · · · · · · · · ·			ASA.VV					.VH.	II		IIA.
HeNXY-China-2016			l	.		ASA.VV					.VH.	II		IIA.
HeNXP-China-2016			. I	.		ASA.VV					.VH.	II		IIA.
HeNJYG-China-2015			••••• •••• I	.		ASA.VV					.VH.	II		IIA.
HeNFJC-China-2015		•••••	• • • • • • • • • • • • • • • • • • •			ASA.VV					.VH.	II		IIA.
GDHDYC-China-2016			• • • • • • • • • • • • • • • • • • •			ASA.VV					.VH.	II		IIA.
GD-China-2016		•••••	••••• ••••l	•••••		ASA.VV					.VH.	II		IIA.
GDFC-China-2016		•••••	••••• •••• ·			ASA.VV!					.VH.			IIA.
SDRZ-China-2016		•••••	••••• ••••I			ASA.VV					.VH.	II		IIA.
SDSCL-China-2016		•••••	••••• •••• I	••••••		ASA.VV			•••••		.VH.			ll
HuN-China-2016		•••••	• • • • • • • • • •			ASA.VV				· · · · · · · · · · · · · · · · · · ·	.Х. Н.			II
ZJHY-China-2016		•••••	· · · · · · · · · · · · · · · · · · ·	••••••		ASA.VV			•••••		.VH.			
SX-China-2016		•••••	••••• •••• ·••• ·	••••••		ASA.VV			•••••		.VH.	II		ffA.
JSZL-China-2017		•••••	· · · · · · · · · · · · · · · · · · ·			ASA.VV			• • • • • • • • • • •		.VH.	II		ff
				•			-							




Full-size 🖾 DOI: 10.7717/peerj.5785/fig-6

From the 1990s until late 2011, >80% of pigs in China were vaccinated with the Bartha-K61 vaccine, and pseudorabies was well controlled (*Yu et al., 2014*). This could be reflected by the unpublished data from Huazhong Agricultural University Diagnostic Center for Animal Infectious Diseases (Wuhan, China) which indicated that the detective

						T T							11.11		mm		1111
	50		0		110 120	10	130	140	150	16	j '	170	180	190	200	210	10
Becker-USA	WD-LSTE	GDDDLD	DLNG	VAG	IWTELEVROCDAVA	TMVC	ETACHPDLY	LGRACVPEA	ERGI	DYLPPEVE	RLORE	PRIVIPERWSPH	LTVR	ATPNDTGLYTLHD	ASGPRAVE	EVAVGDRPP	PLA
Kaplan-Hungary			• • • •			.T.,					R		· · · Q.				
NIA3-Japan		N															
Fa-China-2001	D	N	D.	I.,		.T.,			.M		.R.,		.S.L.				.AD
Min-A-China-2002		N	D.	ī.,		.T.,			.N		R		.S.L.				aD
Ea-China-1999	D	N	D.	I.,		.1					R		.S.L.				AD
HeN1-China-2012	D	DN.	D.	L		.T.,			.M		R		.S.L.				
TJ-China-2012	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				.AD
HuBHC-China-2016	D	DN.	D.	I.,		.T.,			.M		R.,		.S.L.				AD
HuBYCYJ-China-2016		DN.	D.	Ι.,		.T.,					R		.S.L.				AD
HuBWX-China-2016	D	DN.	D.	L		.T.,			.M		R		.S.L.				
HuBZX-China-2016	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				AD
HuBAL-China-2016	D	DN.	D.	ī.,		.T.,			.M		R		.S.L.				AD
HuBHZ-China-2016	D	DN.	D.	Ι.,		.T.,			. M		R		.S.L.				AD
HuBLLP-China-2016	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				AD
HuBQJ-China-2016	D	DN.	D.	L.,		.T.,			.M		R		.S.L.				AD
HuB-China-2016	DR	N.		ī.,		.T.,			.M		R		.S.L.				aD
HuBSP-China-2017	D	DN.	D.	I.,		.T.,			. M	G.	R		.S.L.				AD
FJFQ-China-2016	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				
HeNZZZM-China-2016		DN.	D.	L.,		.T.,			.M		R		.S.L.				AD
HeNXY-China-2016	D	DN.	D.	ī.,		.T.,			.M		R.,		.S.L.				aD
HeNXP-China-2016	D	DN.	D.	Ι.,		.T.,			.M		R		.S.L.				AD
HeNJYG-China-2015	D	DN.	D.	L.,		.T.,			.M		R		.S.L.				AD
HeNFJC-China-2015	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				AD
GDHDYC-China-2016	D	DN.	D.	ī.,		.Ŧ.,			.M		R		.S.L.				BD
GD-China-2016	D	DN.	D.	Ι.,		.T.,			.M		R		.S.L.				AD
GDFC-China-2016	D	DN.	D.	I.,		.T.,			.M		R.,		.S.L.				ZD
SDRZ-China-2016	D	DN.	D.	L.,		.T.,			.M		R		.S.L.				AD
SDSCL/China/2016	D	DN.	D.	ī.,		· 7			.M		R.,		.S.L.	***********			BD
HuN-China-2016	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				AD
ZJHY-China-2016	D	DN.	D.	I.,		.T.,			.M		R		.8.L.				AD
SX-China-2016	D	DN.	D.	I.,		.T.,			.M		R		.S.L.				AD
JSZL-China-2017	D	DN.	D.	ī.,		·7			.M		R.,		.S.L.	***********			AD

i i i i i i i i i i i i i i i i i i i	460	470		480	490	500	510	520		30	540	550	560	570	58
Becker-USA	CVLCSRRRAASRP	RVPTR	GTRML	SPVYTSLPTS	EDYYDGDDDD	E	GDA-RRBPSS	GGDSGYEGI	YVSLDAE	EFSSDEI	DGLYVRPER	APRSGEDVWE	RDPEKPEVT	NGPNYGV	ASRI INAR
Kaplan-Hungary															
NIA3-Japan							.7								
Fa-China-2001			R.H.				.VI		.lP.						.NMS.
Min-A-China-2002			R.H.,		DD		.VIA.		.AP.						.N. MS.
Ea-China-1999			R.H.				.VIA.		.AF.						.NMS.
HeN1-China-2012			R.H.				.VIA.	S	.AP.						.N
TJ-China-2012			R.H.				.VIA.		.aP.						.NMS.
HuBHC-China-2016			R.H.				.VI	3	.AP.						N. MS.
HuBYCYJ-China-2016			R.H.				.VIA.	S	.AF.						.NMS.
HuBWX-China-2016			R.H.		D		.VIA.	s	.A						.N MS.
HuBZX-China-2016			R.H.				.VI		.aP.						.NMS.
HuBAL-China-2016			R.H.				.VI	s	.AP.						N MS.
HuBHZ-China-2016			R.H.				.VI		.A						.N MS.
HuBLLP-China-2016			RMH .				.VI	g	.AP.						.N MS.
HuBQJ-China-2016			R. H.				.VI	3	.AP.						.N MS.
HuB-China-2016			R.H.	contraction of the			. VV A.		.a.,P.			1997 - 1997 - 1972 - 1972 - 1973 - 1977 1997 - 1997 - 1972 - 1972 - 1973 - 1977	And the second second		N. MS.
HuBSP-China-2017		10.1	R.H.				.VI	S	.A						N MS.
FJFO-China-2016			R. H.				.VI	3	.A						.N MS.
HeNZZZM-China-2016			R.H.				VIA.	3	.a., p.						N MS.
HeNXY-China-2016	A CONTRACTOR OF A CONTRACT OF	A COLORED	R. H.	a characteristic de la companya de l	- n.		VT. A.	9	1 p	C. C. C. C. C. C. C.		and strategy and some of		100.000	N. MS.
HeNXP-China-2016			R.H.		n	Ш	VT. A		1 P						N. MS.
HeNJYG-China-2015			R. H.		- D.	П	VT.	9	1. P.						N. MS.
HeNFJC-China-2015			R. H.		Π		VT 1	3	a. p.						N. MS.
GDHDYC-China-2016			R. H.		- D	1	VT 1	9	2 P					10000000	N. MS
GD-China-2016			R.H.		п	11	VT. A	g	1. P.						N. MS.
SDFC-China-2016			R. R.		n	1	VT 3	9	5 P.						N. MS.
SDRZ-China-2016			R.H.		n	÷1	VI.	9	5 0	п					N. MS.
BDSCL/China/2016			R.H.		Π.	~1	UT 1		3 0					1002000	N. MS
HuN-China-2016			R.H.		- D	1	VT 1		2 0						TN. MS.
JHY-China-2016			R.H.		T	1	VT à		5 D						N. MS.
SUMT-China-2016 SX-China-2016			R. 8.			1	VT. 1	0	A.GP.						N. MS.
JSZL-China-2015			B.B.			21	.VI	0	.AP.						N. MS.
JSZL-China-2017		10.000	S. I.		· · · · · · · · · · · · · · · · · · ·	- 1	· Y1	a	·						.n., MS.



Full-size DOI: 10.7717/peerj.5785/fig-7

rate of PRV in mainland China between 2010 and 2011 was lower than 6%. However, the positive rate of PRV increased to approximately 12% between 2012 and 2013 as revealed by this study. These findings suggest that receiving the Bartha-K61 vaccine is likely to be unable to provide full protection against the PRVs circulating in China after 2011. Actually, this suggestion has been confirmed in laboratory (*An et al., 2013; Yu et al., 2014*).

The results from this study showed that the positive rate of PRV detection had a significant decreasing after 2013, this might be because several vaccines based on the epidemic strains have been developed after the 2011 outbreak, and the use of these vaccines helps to decrease the infection of the virus (*Wang et al., 2014*; *Hu et al., 2015*).

It has been reported that PRV isolates are generally divided into two genotypes according to the gC gene; PRV strains prevalent in China belong to genotype II while PRV isolates from the other countries belong to genotype I (Ye et al., 2015). In agreement with this report, the isolates analyzed in this study were divided into two distinct clusters according to their gC genes, with the previously reported genotype I strains Bartha, Backer, Kaplan and NIA3 forming one cluster and the Chinese strains including the reported genotype II strains TJ, JS, and HeN1 forming the second cluster (Fig. 4B). Interestingly, similar results were also obtained when using gB and gE to perform the phylogenetic analysis (Figs. 4A and 4C). Those findings again confirm that PRV strains circulating in China harbor different genotypes from those spreading in the other countries. This observation also might be the reason that the Bartha-K61 vaccine was unable to provide full protection against these emergent strains. Interestingly, one isolate, HuB-China-2016, belonged to genotype II according to gC and gE, but was identified as a genotype I strain when using gB as a phylogenetic criterion (Fig. 4). These findings suggest that a genetic recombination might have occurred within the genome of this isolate. In the next step of this investigation, we intend to do a follow up study in which the whole genome will be sequenced in order to clarify what happened with this strain.

The gB protein is the most conserved glycoprotein in herpesviruses and allows PRV strains to enter the target cells, thus contributing directly to cell-to-cell spread (*Mettenleiter*, 2003). In addition, this gB protein is the principle immunogen of the virus, stimulating the host to produce both complement-dependent and non-complement dependent neutralizing antibodies (*Okazaki, 2007*). Alignments of the gB protein indicated that the Chinese strains had amino acid insertions, deletions, and substitutions in comparison with strain Bartha-k61 (Fig. 5). These amino acid changes might lead to the alteration of the neutralizing epitope of the gB protein and thus alter the protective efficacy of previously used Bartha-k61vaccines in China.

The gC protein is another important neutralizing antigen and is the major virulent protein of PRV, guiding the adsorption process between the virus and target cells (*Karger, Schmidt & Mettenleiter, 1998*). Sequence alignments of the gC protein found that the most Chinese strains contained a continuous insertion of seven amino acids (AAASTPA at sites 63-69) and two-amino acid substitution within the protein compared to Bartha-k61 (Fig. 6). These changes might influence the structure of the gC glycoprotein of those strains, and therefore influence the virus adhesion to host cells. The gE protein is another major virulent protein of PRV (*Wang et al., 2015*). It has been reported that only a few amino acids changes are required to alter the virulence of PRV isolates (*Mettenleiter et al., 1994*). In this study, we found that the 25 PRV strains contained amino acid-insertion/deletion within the gE protein either compared to the isolates from other countries (Kaplan-Hungary and

NIA3-Japan) or compared to the isolates from China before 2012 (strain Min-A-China-2002); those changes might also have an effect on the virulence of PRV isolates currently circulating in China.

CONCLUSION

In summary, this study reported a large-scale etiological investigation of PRV involved in most regions of China after the outbreak of PR in late 2011. Our data revealed an average positive rate of 8.27% for PRV detection between 2012 and 2017, indicating the risk of pseudorabies prevalence in China. Phylogenetic analysis showed that the evolutionary relationship between the PRV isolates circulating in China and those from the other countries was remarkably distinct, suggesting that vaccination with foreign strains might be unable to provide full protection against currently epidemic isolates in China. In addition, PRV isolates currently circulating contained different types of mutations within their gB, gC, and gE proteins compared to those from other countries and/or those from China before the outbreak; these changes also might be associated with virulence changes of the virus. In the next step, we intend to evaluate the influence of those changes on the virulence/pathogenicity of the isolates.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by the National Key R&D Program of China (Grant number: 2018YFD0500800), and the National Key Technology Support Program of China (Grant number: 2015BAD12B04). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors: National Key R&D Program of China: 2018YFD0500800. National Key Technology Support Program of China: 2015BAD12B04.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Ying Sun, Qingyun Liu and Tingting Zhao performed the experiments, prepared figures and/or tables, approved the final draft.
- Wan Liang performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Hechao Zhu and Lin Hua performed the experiments, approved the final draft.

- Zhong Peng conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Xibiao Tang conceived and designed the experiments, approved the final draft.
- Charles W. Stratton and Yongxiang Tian authored or reviewed drafts of the paper, approved the final draft.
- Danna Zhou analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.
- Huanchun Chen conceived and designed the experiments, authored or reviewed drafts of the paper, approved the final draft.
- Bin Wu conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, approved the final draft.

Data Availability

The following information was supplied regarding data availability:

NCBI GenBank with a BioProject ID: PRJNA250865 sequences are also available in the Supplemental File.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.5785#supplemental-information.

REFERENCES

- An TQ, Peng JM, Tian ZJ, Zhao HY, Li N, Liu YM, Chen JZ, Leng CL, Sun Y, Chang D, Tong GZ. 2013. Pseudorabies virus variant in Bartha-K61-vaccinated pigs, China, 2012. *Emerging Infectious Diseases* 19:1749–1755 DOI 10.3201/eid1911.130177.
- Hu RM, Zhou Q, Song WB, Sun EC, Zhang MM, He QG, Chen HC, Wu B, Liu ZF. 2015. Novel pseudorabies virus variant with defects in TK, gE and gI protects growing pigs against lethal challenge. *Vaccine* **33**:5733–5740 DOI 10.1016/j.vaccine.2015.09.066.
- **Karger A, Schmidt J, Mettenleiter TC. 1998.** Infectivity of a pseudorabies virus mutant lacking attachment glycoproteins C and D. *Journal of Virology* **72**:7341–7348.
- Kimman TG, De Wind N, Oei-Lie N, Pol JM, Berns AJ, Gielkens AL. 1992. Contribution of single genes within the unique short region of Aujeszky's disease virus (suid herpesvirus type 1) to virulence, pathogenesis and immunogenicity. *Journal of General Virology* 73(Pt 2):243–251 DOI 10.1099/0022-1317-73-2-243.
- Liu Y, Zhang S, Xu Q, Wu J, Zhai X, Li S, Wang J, Ni J, Yuan L, Song X, Zhao B,
 Zhou Z, Wang C, Yang L. 2018. Investigation on pseudorabies prevalence in
 Chinese swine breeding farms in 2013–2016. *Tropical animal Health and Production* 50(6):1279–1285 DOI 10.1007/s11250-018-1555-1.
- Luo Y, Li N, Cong X, Wang CH, Du M, Li L, Zhao B, Yuan J, Liu DD, Li S, Li Y, Sun Y, Qiu HJ. 2014. Pathogenicity and genomic characterization of a pseudorabies virus variant isolated from Bartha-K61-vaccinated swine population in China. *Veterinary Microbiology* 174:107–115 DOI 10.1016/j.vetmic.2014.09.003.

- Mettenleiter TC. 2000. Aujeszky's disease (pseudorabies) virus: the virus and molecular pathogenesis—state of the art, 1999. *Veterinary Research* **31**:99–115.
- Mettenleiter TC. 2003. Pathogenesis of neurotropic herpesviruses: role of viral glycoproteins in neuroinvasion and transneuronal spread. *Virus Research* 92:197–206 DOI 10.1016/S0168-1702(02)00352-0.
- Mettenleiter TC, Klupp BG, Weiland F, Visser N. 1994. Characterization of a quadruple glycoprotein-deleted pseudorabies virus mutant for use as a biologically safe live virus vaccine. *Journal of General Virology* **75**(Pt 7):1723–1733 DOI 10.1099/0022-1317-75-7-1723.
- Muller T, Hahn EC, Tottewitz F, Kramer M, Klupp BG, Mettenleiter TC, Freuling C. 2011. Pseudorabies virus in wild swine: a global perspective. *Archives of Virology* 156:1691–1705 DOI 10.1007/s00705-011-1080-2.
- Nauwynck H, Glorieux S, Favoreel H, Pensaert M. 2007. Cell biological and molecular characteristics of pseudorabies virus infections in cell cultures and in pigs with emphasis on the respiratory tract. *Veterinary Research* 38:229–241 DOI 10.1051/vetres:200661.
- **Ober BT, Summerfield A, Mattlinger C, Wiesmuller KH, Jung G, Pfaff E, Saalmuller A, Rziha HJ. 1998.** Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+CD8+ memory T-helper cells in swine. *Journal of Virology* **72**:4866–4873.
- **Ober BT, Teufel B, Wiesmuller KH, Jung G, Pfaff E, Saalmuller A, Rziha HJ. 2000.** The porcine humoral imMune response against pseudorabies virus specifically targets attachment sites on glycoprotein gC. *Journal of Virology* **74**:1752–1760 DOI 10.1128/JVI.74.4.1752-1760.2000.
- **Okazaki K. 2007.** Proteolytic cleavage of glycoprotein B is dispensable for in vitro replication, but required for syncytium formation of pseudorabies virus. *Journal of General Virology* **88**:1859–1865 DOI 10.1099/vir.0.82610-0.
- Peng J, An T, Zhao H, Liu Y, Chen J, Leng C, Sun Y, Chang D, Tian Z, Tong G. 2013. Identification and antigenic variation of new epidemiology of pseudorabies virus from swine. *Chinese Journal of Veterinary Medicine* 35:1–4.
- **Pomeranz LE, Reynolds AE, Hengartner CJ. 2005.** Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. *Microbiology and Molecular Biology Reviews* **69**:462–500 DOI 10.1128/MMBR.69.3.462-500.2005.
- Sozzi E, Moreno A, Lelli D, Cinotti S, Alborali GL, Nigrelli A, Luppi A, Bresaola M, Catella A, Cordioli P. 2014. Genomic characterization of pseudorabies virus strains isolated in Italy. *Transboundary and Emerging Diseases* 61:334–340 DOI 10.1111/tbed.12038.
- Tong G, Chen H. 1999. Pseudorabies epidemic status and control measures in China. *Chinese Journal of Veterinary Science* 19:1–2.
- Wang Y, Qiao S, Li X, Xie W, Guo J, Li Q, Liu X, Hou J, Xu Y, Wang L, Guo C, Zhang G. 2015. Molecular epidemiology of outbreak-associated pseudorabies virus (PRV) strains in central China. *Virus Genes* 50:401–409 DOI 10.1007/s11262-015-1190-0.
- Wang CH, Yuan J, Qin HY, Luo Y, Cong X, Li Y, Chen J, Li S, Sun Y, Qiu HJ. 2014. A novel gE-deleted pseudorabies virus (PRV) provides rapid and complete protection

from lethal challenge with the PRV variant emerging in Bartha-K61-vaccinated swine population in China. *Vaccine* **32**:3379–3385 DOI 10.1016/j.vaccine.2014.04.035.

- Ye C, Zhang QZ, Tian ZJ, Zheng H, Zhao K, Liu F, Guo JC, Tong W, Jiang CG, Wang SJ, Shi M, Chang XB, Jiang YF, Peng JM, Zhou YJ, Tang YD, Sun MX, Cai XH, An TQ, Tong GZ. 2015. Genomic characterization of emergent pseudorabies virus in China reveals marked sequence divergence: evidence for the existence of two major genotypes. *Virology* 483:32–43 DOI 10.1016/j.virol.2015.04.013.
- Yu X, Zhou Z, Hu D, Zhang Q, Han T, Li X, Gu X, Yuan L, Zhang S, Wang B, Qu P, Liu J, Zhai X, Tian K. 2014. Pathogenic pseudorabies virus, China, 2012. *Emerging Infectious Diseases* 20:102–104 DOI 10.3201/eid2001.130531.
- Yuan Q, Wu Y, Li Y, Li Z, Nan X. 1983. The pseudorabies vaccination research. I: pseudorabies attenuated vaccine research. *Chinese Journal of Veterinary Medicine* 1:1–6.